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Summary Breast cancer cells are known to express various proteolytic enzymes, which make them invasive
and favour their dissemination to distant sites. However, it is unclear whether breast cancer cells have the
ability to produce polymorphonuclear leucocyte elastase (PMN-E). We measured immunoreactive (ir) PMN-E
content in the conditioned medium of two breast cancer cell lines, MCF-7 and ZR-75-1, and two normal
breast epithelial cell lines, HBL-100 and Hs 578Bst, using a highly specific and sensitive enzyme immunoassay.
Furthermore, ir-PMN-E content was determined in tissue extracts from 62 human breast cancers. ir-PMN-E
content in the culture medium of MCF-7 cells and ZR-75-1 cells increased as a function of time, regardless of
the presence or absence of oestradiol. On the other hand, no detectable ir-PMN-E was secreted into the
culture medium of HBL-100 and Hs 578Bst cells. ir-PMN-E was detectable in 59 of 62 tissue extracts prepared
from human breast cancers, the concentration ranging from 0.12 to 19.17 fig per 100 mg of protein. When 62
breast cancer specimens were categorised into four groups in terms of clinical stage, ir-PMN-E content in
breast cancer tissue was significantly higher in stage III (8.90 ± 5.13 jg 100 mg-' protein) and stage IV
(12.19± 5.44lg 100mg' protein) patients than in stage I (1.64±1.54pg 100mg' protein) and stage II
(4.23 ± 3.74 gg 100 mg-' protein) patients. Breast cancer patients with high levels of ir-PMN-E showed
significantly shorter disease-free survival and overall survival than those with low levels of ir-PMN-E at the
cut-off point of 8.99 lg 100 mg-' protein. In the multivariate analysis, ir-PMN-E content was found to be a
significant prognostic factor for disease recurrence and death in human breast cancer.
Considerable evidence suggests that proteolytic enzymes are
involved in cancer invasion and metastasis (Mignatti et al.,
1986; Persky et al., 1986). Production of tumour cell pro-
teinases, including plasminogen activator (Duffy et al., 1987;
Reich et al., 1988; Yamashita et al., 1993a), collagenase
(Turpeenniemi-Hujanen et al., 1985), and cathepsin B (Reck-
lies et al., 1980) has been implicated in tumour cell invasion
into adjacent tissues and metastasis. Another proteinase that
has attracted attention as a mediator of these processes is
elastase. Elastase is the only proteinase that is able to de-
grade insoluble elastin (Janoff & Schere, 1968), a structural
component of elastic tissues such as blood vessels, skin, lung
and breast tissue.
An elastinolytic activity has been demonstrated previously
by Hornebeck et al. (1977) in tissue extracts from human
breast cancer, but in their study it was not determined wheth-
er the activity could be attributed to tumour cells. Thereafter,
several investigators have reported that elastinolytic activity
is found in the culture medium of mouse mammary tumour
cells (Grant et al., 1990; Zeydel et al., 1986) and human
breast cancer cells (Kao et al., 1982), suggesting that elas-
tinolytic enzymes are produced by the tumour cells
themselves.
Very recently, a highly specific and sensitive enzyme
immunoassay (EIA) was established for the measurement of
human polymorphonuclear leucocyte elastase (PMN-E) (Ikei
et al., 1992). Labelled antibody in this assay recognises not
only PMN-E complexed a,-proteinase inhibitor but also the
free form of PMN-E, which may present in the enzyme
samples. In the present study, we examined whether breast
cancer cells have the ability to produce immunoreactive (ir)-
PMN-E. Furthermore, we have determined the concentration
of ir-PMN-E in tissue extracts from human breast cancer,
and elucidated the relationship between the tissue content of
ir-PMN-E and clinicopathological status in human breast
cancer.
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Materials and methods
Cell culture
The human breast cancer cell line MCF-7 was kindly pro-
vided by Y. Nomura (National Kyushu Cancer Center Hos-
pital, Fukuoka, Japan). The human breast cancer cell line
ZR-75-1 (passage 82) and two normal breast epithelial cell
lines, HBL-100 and Hs 578Bst, were obtained from the
American Type Culture Collection (ATCC, Rockville, MD,
USA). These four cell lines were maintained in 25 cm2 plastic
tissue culture flasks containing RPMI medium at 37°C in a
95% room air-5% carbon dioxide humidified incubator. The
culture media for these cell lines were supplemented with
10% fetal bovine serum. When the cells had grown to 90%
confluence, the culture medium of each flask was replaced
with a serum-free RPMI medium by washing with the same
medium. Each culture flask was subjected to further incuba-
tion for various times, as indicated in the Results section, in
the presence of oestradiol or the vehicle. Oestradiol dissolved
in 0.1% ethanol was added at the final concentration of
10-8 M. Finally, the culture media were collected and ir-
PMN-E concentration determined as described below. The
viability of the cultured cells was greater than 99% when
determined by a dye exclusion method with trypan blue.
Human breast tumours
The 62 breast cancer patients analysed in this study were
those who underwent curative or non-curative mastectomy in
the Department of Surgery II, Kumamoto University
Medical School, during the 3 year period from 1982 to 1984.
Immediately after surgical removal, 62 human breast cancers
were stored at - 80°C until extraction.
The medical records of these 62 patients were evaluated
retrospectively in this study. The median follow-up period for
patients with low levels of ir-PMN-E was 7.9 years (range
7.3-9.2 years) and for patients with high levels it was 8.2
years (range 7.6-9.5 years). Every death in this study was
due to metastatic breast cancer. The clinicopathological
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parameters studied were age, tumour size, number of positive
nodes, presence or absence of distant metastasis, histological
type, histological grade, oestrogen receptor and progesterone
receptor. Tumour size was measured as the greatest diameter
of the tumour. The extent of lymph node metastasis was
categorised into one of three groups: 0, 1 to 3 and 4 +. All
carcinomas were staged according to the International Union
Against Cancer (UICC) TNM classification. When breast
cancers were histologically typed according to the WHO
(1981) classification, all of 62 tumours in our series were
classified into the same category, i.e. invasive ductal car-
cinoma. Therefore, each tumour was further analysed accord-
ing to the classification of the Japanese Breast Cancer Society
(1989) and was graded in parallel according to the criteria
described by Bloom and Richardson (1957).
Assayfor ir-PMN-E content
The extract of each specimen was prepared as described
previously (Yamashita et al., 1986). Briefly, each frozen tissue
(0.2 g) was quickly thawed at room temperature, minced and
rinsed with ice-cold 0.1 M Tris-HCI buffer, pH 7.4. Minced
pieces were finally suspended in 2 ml of 50 mM Tris-HCI
buffer (pH 7.4) containing 0.25% Triton X-100, followed by
homogenisation and centrifugation at 12,000g for 20 min at
4°C. The resulting supernatant was assayed for ir-PMN-E
content as described below.
ir-PMN-E content in tissue extracts was determined by a
newly established EIA kit (Mochida Pharmaceutical, Tokyo,
Japan). The justification for the assay method using this kit
has been reported by one of the co-authors (Ikei et al., 1992).
This is a sensitive assay that enables rapid measurement of
both PMN-E-complexed al-proteinase inhibitor and the free
form of PMN-E, which may be present in the enzyme sam-
ples, in contrast to the conventional Merck EIA kit (E.
Merck, Darmstadt, Germany), which detects only PMN-E
complexed with xl-proteinase inhibitor (Neumann et al.,
1984). When 0.1 ml of tissue extract was used, the detection
limit of ir-PMN-E was 0.063 1ig per 100 mg of protein. For
estimation of the reproducibility of the assay method, three
samples were chosen and each sample was measured ten
times. The coefficient of variation of standard deviation was
4.0-5.8%. Prior to the experiment, we confirmed that a
serial dilution curve of conditioned medium from two human
breast cancer cell lines and tissue extracts from human breast
cancer exhibited parallelism with that of standard PMN-E in
the present assay.
Statistical analysis
Kruskal-Wallis tests were used for the analysis of ir-PMN-E
content in relation to clinicopathological factors. Analyses of
disease-free and overall survival were performed using the
Kaplan-Meier method (Kaplan & Meier, 1958). Tests of
differences between curves were made with the log-rank test
(Mantel, 1966) for censored survival data. The Cox's propor-
tional hazards model (Cox, 1972) was used in the multi-
variate analysis to assess the independent prognostic
significance.
Results
Production ofir-PMN-E in human breast cancer cells
As shown in Figure la, ir-PMN-E content of the culture
medium increased with time in ZR-75-1 cells, regardless of
the presence or absence of 10-8 M oestradiol, a concentration
equivalent to physiological levels. A similar result was
obtained using MCF-7 cells (Figure lb). However, the
amount of the enzyme released into the culture medium of
MCF-7 cells was about half of that for ZR-75-1 cells. In
sharp contrast to breast cancer cell lines, no detectable
amount of ir-PMN-E was secreted into the conditioned
(x 10-2)
5
")
0 w
E
E
0 81)
E
0
.0
O (X10-2)
C._
8) c CD
0
z 0~ 2~ 5
a
6 12 18 24
b
0 6 12
Time (h)
18 24
Figure 1 Release of ir-PMN-E from human breast cancer cell
lines, ZR-75-1 (a) and MCF-7 (b), as a function of time. After
adding 10-8 M oestradiol (0) or the vehicle (@), cells were
incubated for various times, and ir-PMN-E content in condi-
tioned medium was measured at the indicated times using an
EIA. Each bar represents the mean ± s.d. of three individual
experiments.
medium of two normal breast epithelial cell lines, HBL-100
and Hs 578Bst, at any of the times tested.
ir-PMN-E content in tissue extractsfrom human breast cancer
To examine the proportion of the free form of ir-PMN-E to
the content of ir-PMN-E bound to a,-proteinase inhibitor in
tissue extracts from human breast cancer, we determined the
ir-PMN-E content in 12 tissue extracts in the presence and
absence of an excess amount (100figml') of a,-antitrypsin
(Sigma, St Louis, MO, USA) using the conventional Merck
kit according to the method of Neumann et al. (1984). By
using serial amounts of a,-antitrypsin, this quantity was
confirmed to be completely saturating under the present
assay conditions. Since the Merck kit detects PMN-E com-
plexed with a,-proteinase inhibitor only, the difference74 J.-I. YAMASHITA et al.
between these contents was regarded as the free-form ir-
PMN-E content. As shown in Figure 2, the ratio offree-form
ir-PMN-E content to total ir-PMN-E content in tissue ex-
tracts varies over a wide range, between 5.6% (case 5) and
77.8% (case 3) of the total ir-PMN-E content.
By using a new EIA kit that detects both forms of PMN-
E, ir-PMN-E was detected (sensitivity > 0.063 pg 100 mg-1
protein) in the extracts from 59 of 62 specimens, the concen-
tration ranging from 0.12 to 19.17pg lOOmg'1 protein
(Figure 3). ir-PMN-E was also detected in tissue extracts
from one (1.15 pg 100 mg-' protein) of seven fibroadenomas
and none of five normal mammary tissues. When 62 breast
cancer specimens were categorised into four groups in terms
of clinical stage according to the TNM classification of
UICC, ir-PMN-E content was significantly higher in stage III
(8.90 ± 5.13 pg 100 mg'1 protein) and stage IV (12.19 ±
5.44fpg lOOmg-' protein) patients compared with either
stage I (1.64± 1.54pg lOOmg-' protein) or stage II
(4.23 ± 3.74 pg 100 mg-' protein) patients (Figure 3).
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Figure 2 ir-PMN-E contents were measured in 12 tissue extracts
with ( ) and without ( ) excess a,-antitrypsin using the
conventional Merck kit as described in the Results section. The
difference between these contents was regarded as free-form ir-
PMN-E content unbound to ml-proteinase inhibitor.
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Figure 3 Distribution of ir-PMN-E contents in breast cancer
tissue extracts. Specimens of 62 breast cancer were categorised in
terms of clinical stage. Numbers in parentheses are the number of
patients. Each bar represents the mean ± s.d. Statistically
significant difference between the groups: P<0.05, "P<0.01 or
***P<0.0001.
Relation ofir-PMN-E content to clinicopathologicalfactors
Table I shows the correlation between ir-PMN-E content and
the characteristics of the patients in this series. When ir-
PMN-E content was compared in terms of age, histological
type, histological grade, oestrogen receptor and progesterone
receptor, no significant association was found between ir-
PMN-E content and any of these features. However, ir-
PMN-E content was significantly higher in tumours with a
size of more than 2.1 cm compared with those less than
2.1 cm. Similarly, ir-PMN-E content was significantly higher
in patients with lymph node involvement or distant meta-
stasis than in metastasis-negative patients.
Relation ofir-PMN-E content to survivial
To evaluate the prognostic significance of ir-PMN-E, we
analysed disease-free survival and overall survival in breast
cancer patients. Patients with metastatic disease at the time
of primary therapy were excluded from these analyses. The
optimal cut-off point of 8.99 pg 100 mg-' protein was deter-
mined to give a statistically significant separation for risk of
death by the method of Tandon et al. (1990). As shown in
Figure 4, patients with breast cancer tissue containing a high
level of ir-PMN-E content had a significantly shorter disease-
free survival (P<0.01) and overall survival (P<0.02) time
than those with a low level of the enzyme content. In mul-
tivariate analysis including all variables, node status and
ir-PMN-E were found to be independent prognostic factors
for recurrence and for death (Table II).
Discussion
There are three well-characterised mammalian elastases. The
best characterised is the porcine pancreatic elastase I, first
Table I Relation between PNM-E content in tissue extracts and
clinicopathological factors of human breast cancer
Factors PMN-E contenta (jug 100mg' protein)
Age (years)
<50 (28)b 5.27 ± 4.01
>50 (34) 4.15 3.39
Tumour size (cm)
Ti: 0-2.0 (11) 1.26 1.15C
T2: 2.1-5.0 (35) 4.72 3.66d
T3: >5.1 (16) 8.31 5.64
No. of positive nodes
0 (22) 2.42+ 1.73C
1-3 (19) 4.35 3.96
>4 (21) 6.47 5.30
Distant metastases
MO: absent (49) 3.73 ± 3.36'
Ml: present (13) 9.00 5.53
Histological type
Papillotubular (13) 3.62 ± 3.19
Solid tubular (27) 4.70± 3.91
Scirrhous (22) 5.81 ± 3.85
Histological grade
Grade I (19) 4.24± 3.67
Grade II (22) 4.36± 3.83
Grade III (21) 5.99 ± 5.01
Oestrogen receptor
Negative (30) 5.72 ± 4.13
Positive (32) 4.03 ± 3.36
Progesterone receptor
Negative (21) 5.38 ± 4.24
Positive (41) 4.29 ± 3.62
aMean ± s.d. bNumbers in parentheses are the number of patients.
cP <0.002 compared with 2.1-5.0cm; P <0.001 compared with
>5.1cm. dp <0.01 compared with >5.1 cm. CP<0.05 compared
with 1-3; P <0.002 compared with >4. fP <0.001 compared with
present.
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Figure 4 Disease-free and overall survival curves in breast
cancer patients according to ir-PMN-E content in tumour ex-
tracts. Patients with distant metastasis at the time of primary
therapy were excluded from this analysis. The number of patients
in each group was as follows: < 8.99lAg 100 mg-' protein, 43;
and >8.99 jug 100 mg- protein, 6.
Table II Variables that significantly contributed to prediction of
disease recurrence and survival in Cox's regression model
Recurrence Death
Variables RRa P-value RR P-value
Lymph node metastases>4 2.05 0.031 1.95 0.031
ir-PMN-E>9.12 3.23 0.036 2.87 0.046
aRR: Relative risk. bValues for patients with distant metastases
were excluded from the analysis for disease recurrence and death.
described by Balo and Banga (1949), which is a serine pro-
teinase secreted in a zymogen form by pancreatic acinar cells.
The second class of mammalian elastase is PMN-E, the
neutral proteinase found in the granules of human polymor-
phonuclear leucocytes (Janoff & Schere, 1968; Baugh &
Travis, 1976). A third mammalian elastase is a metallo-
proteinase, secreted by inflammatory macrophages (Banda &
Werb, 1981).
The presence of elastinolytic activities in human breast
cancer tissue has been demonstrated by Hornbeck et al.
(1977), but in their study it was not determined whether the
activity could be attributed specifically to breast cancer cells.
Thereafter, several investigators have described elastinolytic
enzyme production by human and rodent mammary tumour
cells (Kao et al., 1982; Zeydel et al., 1986; Grant et al., 1990).
However, these enzymes have not been isolated or charac-
terised. In the present study, we demonstrated that ir-PMN-E
was produced by two breast cancer cell lines, MCF-7 and
ZR-75-1, regardless of the presence or absence of oestradiol,
suggesting that the mechanism responsible for this enzyme
production seems to be oestrogen independent, in contrast to
plasminogen activator production, which is regulated by oest-
rogen via an oestrogen receptor system in breast cancer cells
(Yamashita et al., 1984; Mira-y-Lopez et al., 1991; Inada et
al., 1992). In addition, we revealed that two normal breast
epithelial cell lines, HBL-100 and Hs 578Bst, produced no
detectable ir-PMN-E. In a separate investigation, we showed
that PMN-E immunoreactivity is seen solely in the breast
cancer cells and not in the stromal cells (data not shown),
suggesting that P.MN-E is synthesised by the epithelial com-
ponent of breast cancer tissues.
The present study also revealed that two forms of ir-PMN-
E, a free form and an inhibitor-complexed form, exist in
tissue extracts from human breast cancer. A significant
positive correlation was found between ir-PMN-E content in
tissue extracts and clinical stage of primary breast cancer.
Furthermore, breast cancer patients with high ir-PMN-E
content had a significantly shorter disease-free survival and
overall survival rate than those with low enzyme content.
Our data are preliminary because the number of patients
studied, i.e. 62, was small. However, ir-PMN-E could be
added to the list of other proteinases, such as cathepsin D
(Spyratos et al., 1989; Tandon et al., 1990) and urokinase
plasminogen activator (Duffy et al., 1988; Janicke et al.,
1990), which have been shown to be prognostic markers in
human breast cancer. The variability of ir-PMN-E content
seen in tissue samples does not seem to be due to the
differences in cancer cell content, because scirrhous car-
cinoma, which is characterised by the low cellularity of its
tumour cells, tends to have higher ir-PMN-E content than
two other types, papillotubular carcinoma and solid tubular
carcinoma, although the differences do not reach statistical
significance.
Elastase is the only proteinase that is able to degrade
insoluble elastin (Janoff et al., 1968). Elastase can also hy-
drolyse other proteins, including type IV collagen (Mainardi
et al., 1980), fibronectin (McDonald & Kelley, 1980) and
proteoglycan (Heck et al., 1982). Since the structure of the
penetrated tissues consists mainly of these proteins, the pro-
duction of elastase by cancer cells could increase their
capacity to invade surrounding tissues. Furthermore, elastase
is reported to potentiate the conversion of plasminogen to
plasmin by urokinase-type plasminogen activator (Machovich
& Owen, 1989), which is also synthesised by a number of
tumour cells, including breast cancer cells (Cajot et al., 1986;
Stump et al., 1986). Recently, a direct correlation has been
found between levels of urokinase plasminogen activator
activity and/or concentration and 'metastatic potential in
human and rodent mammary carcinoma (Duffy et al., 1988;
Janicke et al., 1990; Yamashita et al., 1992; 1993b). Col-
lagenase, which may play a role in tumour cell invasion at a
neutral pH, can be activated through plasminogen activator
(Paranjpe et al., 1980). Thus, PMN-E produced by breast
cancer cells may play a pathological role in facilitating cancer
cell invasion and metastasis either directly by dissolution of
the tumour matrix or indirectly through such a proteinase
cascade. A possibility demonstrated here of the existence of a
free (active) form of PMN-E in breast cancer tissues may
support the above assumption.
In conclusion, the present study provides the first evidence
showing that PMN-E is produced by human breast cancer
cells and the amount of this enzyme is closely related to the
progression of human breast cancer.
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